Search Results

You are looking at 111 - 119 of 119 items for :

  • "papillary" x
  • All content x
Clear All
Full access

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

BN Omura GA . Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study) . Gynecol Oncol 1991 ; 41 : 230 – 233 . 152. Kennedy AW Hart WR . Ovarian papillary

Full access

nephrectomy in 565 patients who were treated at 1 of 2 institutions from 2000 to 2009 for clear cell, papillary, or chromophobe RCC with localized disease (N0M0). The primary end point was disease-specific survival (DSS), and disease recurrence (local or

Full access

Peter F. Coccia, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Alberto S. Pappo, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Bradley J. Zebrack, Hema Sundar, and Dorothy A. Shead

dehydrogenase ( SDH ) gene mutations are at risk for paraganglioma and pheochromocytoma, gastrointestinal stromal tumors (GISTs), renal clear cell carcinoma, and papillary thyroid carcinoma during adolescence and young adulthood. Testing for germline mutations

Full access

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson III, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Charles Vollmer Jr., Robert A. Wolff, Brian M. Wolpin, Beth Lynn, and Giby V. George

, NTRK, ROS1 ), mutations ( BRAF, BRCA 1/2, HER2, KRAS, PALB2 ), and MMR deficiency. Premalignant Tumors of the Pancreas Mucinous cystic neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are cystic lesions

Full access

Randall W. Burt, Jamie A. Cannon, Donald S. David, Dayna S. Early, James M. Ford, Francis M. Giardiello, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Kory Jasperson, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, David Weinberg, Mary Dwyer, and Deborah Freedman-Cass

reduction of interglandular stromas with complex irregularity of glands, papillary infolding, and cytogenetic abnormalities) or high-grade dysplasia (severe architectural disturbance of glands along with cytologic features of dysplasia). 107 Carcinoma in

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

of recurrence continues for decades. 10 , 11 Tumor Histology and Grade: Ductal, lobular, mixed, and medullary histologies are considered “usual risk” breast cancers, and tubular, mucinous (colloid), cribriform, papillary, adenoid cystic, and colloid

Full access

Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer

-control study . Br J Cancer 2004 ; 91 : 1829 – 1834 . 10.1038/sj.bjc.6602199 15477862 70. Jazaeri AA , Lu K , Schmandt R , . Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma . Mol Carcinog 2003 ; 36 : 53 – 59

Full access

tertiary care teaching hospital in India over a 2-year period. Restaging TURBT was performed 2–6 weeks after the initial TURBT in all high-grade and T1 tumors. Parameters of the initial TURBT, namely number, appearance (solid vs papillary), size of lesions

Full access

access to diagnostic tools such has MRI, CT, and ultrasonography, pancreatic cystic neoplasms (PCNs) are being detected more frequently. PCNs are classified as mucinous (mucinous cystic neoplasm [MCN] and intraductal papillary mucinous neoplasm [IPMN]) or